Table 2.
Clinical characteristics of patients in published cases
| Case - Year | Age/Gender | Disease | Anti-TNF drug | Immunosuppressant | Dose mg/kg/n-infusions | Symptoms | Autoantibodies | Histology | Steroid response | Outcome |
| 20073 | 56/F | AS | IFX | None | 5/6 | Yes | Anti-dsDNA, ANA, ASMA | Piecemeal necrosis | Yes | Reversibility |
| 20054 | 53/F | PsA | IFX | MTX | 3/8 | No | Anti-dsDNA, ANA, ASMA | Severe interface hepatitis | Yes | Reversibility |
| 200712 | 54/F | RA | IFX | MTX | 3/12 | No | ANA | Chronic inflammation | Yes | Reversibility |
| 20107 | 60/M | CD | IFX | None | 5/4 | No | Anti-dsDNA, ANA, ASMA | Interface hepatitis | Yes | Reversibility |
| 20098 | 22/F | PPP | IFX | None | 5/3 | No | None | Interface hepatitis | Yes | Reversibility |
| 201010 | 40/F | PsO, PsA | IFX | NSAIDS | 5/5 | Yes | Anti-dsDNA, ANA | Chronic hepatitis with portal+periportal fibrosis | Yes | Reversibility |
| 20109 | 37/M | PsO | IFX | None | 5/3 | Yes | Anti-dsDNA, ANA, ASMA Anti-dsDNA, ANA, AMA, anti-cardiolipin | Interface hepatitis | Yes | Reversibility |
| 20109 | 51/M | PsO | IFX | None | 5/3 | Yes | Interface hepatitis + PBC Overlap syndrome | Yes | Reversibility | |
| 200111 | 36/F | RA | IFX | PDN 10 mg | 3/3 | Yes | Anti-dsDNA, ANA | Interface hepatitis | Yes | Reversibility |
| 20106 | 36/F | PsA, PsO, CD | ADA | None | 40 mg EOW 6th injection | Yes | Anti-dsDNA, ANA | Interface hepatitis | Yes | Reversibility |
| 201212 | 46/F | CD | IFX | None | 5/3 | No | ANA, ASMA | Interface hepatitis | Yes | Reversibility |
| 20085 | 30/F | UC | IFX | AZA | 10/> 15 | No | ANA,Anti-dsDNA | Interface hepatitis | Yes | Reversibility |
AS: Ankylosing spondylitis; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; CD: Crohn’s disease; PPP: Palmoplantar pustular psoriasis; PsO: Psoriasis; IFX: Infliximab; ADA: Adalimumab; MTX: Methotrexate; AZA: Azathioprine; EOW: Every other week; dsDNA: Double stranded DNA; ASMA: Anti-smooth muscle antibodies; AMA: Anti-mitochondrial antibodies; PDN: Prednisolone; NSAIDs: Non-steroidal anti-inflammatory drugs; PBC: Primary biliary cirrhosis.